Synlogic, Inc. (SYBX): Price and Financial Metrics

Synlogic, Inc. (SYBX): $3.71

0.04 (+1.09%)

POWR Rating

Component Grades














  • SYBX scores best on the Sentiment dimension, with a Sentiment rank ahead of 88.8% of US stocks.
  • SYBX's strongest trending metric is Value; it's been moving down over the last 31 weeks.
  • SYBX's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).

SYBX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for SYBX is 0 -- better than only 8.12% of US stocks.
  • With a price/sales ratio of 428.36, Synlogic Inc has a higher such ratio than 98.28% of stocks in our set.
  • As for revenue growth, note that SYBX's revenue has grown -77.59% over the past 12 months; that beats the revenue growth of just 2.66% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Synlogic Inc are VBLT, LUMO, IMV, CLDX, and AUTL.
  • Visit SYBX's SEC page to see the company's official filings. To visit the company's web site, go to

SYBX Price Target

For more insight on analysts targets of SYBX, see our SYBX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.71 Average Broker Recommendation 1.38 (Strong Buy)

SYBX Stock Price Chart Interactive Chart >

Price chart for SYBX

SYBX Price/Volume Stats

Current price $3.71 52-week high $5.11
Prev. close $3.67 52-week low $1.78
Day low $3.67 Volume 376,800
Day high $3.85 Avg. volume 834,949
50-day MA $3.50 Dividend yield N/A
200-day MA $2.98 Market Cap 194.29M

Synlogic, Inc. (SYBX) Company Bio

Synlogic, Inc., a biopharmaceutical company, offers synthetic biotics that perform specific metabolic functions from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. It provides SYNB1010 for urea cycle disorder, a synthetic biotic that is designed to remove excess ammonia from the blood; and SYNB2010 for phenylketonuria, a synthetic biotic that is designed to remove excess phenylalanine from the blood. The company was founded in 2013 and is based in Cambridge, Massachusetts.

SYBX Latest News Stream

Event/Time News Detail
Loading, please wait...

SYBX Latest Social Stream

Loading social stream, please wait...

View Full SYBX Social Stream

Latest SYBX News From Around the Web

Below are the latest news stories about Synlogic Inc that investors may wish to consider to help them evaluate SYBX as an investment opportunity.

Synlogic Reminds Stockholders of 2021 Annual General Meeting Details

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on June 10, 2021 at 9:00 am ET. The Annual Meeting will be held in virtual format only via live audio webcast.

Yahoo | June 3, 2021

Synlogic to Present at Upcoming Virtual Banking and Industry Conference

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan, M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of the executive team will present at the following virtual banking and industry conference:

Yahoo | May 25, 2021

Synlogic Presents Data at Digestive Disease Week (DDW) on a Novel Approach for the Treatment of Inflammatory Bowel Disease

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on an investigational program to develop Synthetic Biotic™ medicines for the treatment of inflammatory bowel disease (IBD) during Digestive Disease Week (DDW), being held virtually May 21-23, 2021.

Yahoo | May 23, 2021

Synlogic, Inc. (SYBX) CEO Dr. Aoife Brennan on Q1 2021 Results - Earnings Call Transcript

Synlogic, Inc. (SYBX) Q1 2021 Results Conference Call May 13, 2021 08:30 AM ET Company Participants Daniel Rosan - Senior Vice President and Investor Relations Dr. Aoife Brennan - President and Chief Executive Officer Dr. Richard Riese - Chief Medical Officer Gregg Beloff - Interim Chief Financial Officer Conference Call...

SA Transcripts on Seeking Alpha | May 13, 2021

7 Penny Stocks That May Not Be Penny Stocks For Long

Many penny stocks are destined for bankruptcy, but there are some that will survive.

Mark Putrino on InvestorPlace | April 21, 2021

Read More 'SYBX' Stories Here

SYBX Price Returns

1-mo 17.41%
3-mo -0.27%
6-mo 46.06%
1-year 70.97%
3-year -60.36%
5-year -88.04%
YTD 71.76%
2020 -16.28%
2019 -63.20%
2018 -27.73%
2017 -23.02%
2016 -71.20%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8659 seconds.